Melanocortin receptor-specific peptides for treatment of sexual dysfunction
A melanocortin receptor agonist cyclic peptide of the formula where R, x and y are as defined in the specification, compositions and formulations including the peptide of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes, including sexual dysfunction such as male erectile dysfunction and female sexual dysfunction.
1. A cyclic peptide of formula (I):
including all enantiomers, sterioisomers or diastereoisomers thereof, or a pharmaceutically acceptable salt of any of the foregoing,
wherein:
R is —C(═O)—OH or —C(═O)—NH 2 ;
x is 1 or 2; and
y is 3 or 4.
2. The cyclic peptide of claim 1 of formula (II):
3. The cyclic peptide of claim 1 that is Ac-Arg-cyclo(Asp-Dab-D-Phe-Arg-Trp-Lys)-NH 2 (SEQ ID NO:4).
4. The cyclic peptide of claim 1 that is Ac-Arg-cyclo(Asp-Dab-D-Phe-Arg-Trp-Lys)-OH (SEQ ID NO:5).
5. The cyclic peptide of claim 1 that is Ac-Arg-cyclo(Glu-Dab-D-Phe-Arg-Trp-Orn)-NH 2 (SEQ ID NO:6).
6. The cyclic peptide of claim 1 that is Ac-Arg-cyclo(Glu-Dab-D-Phe-Arg-Trp-Orn)-OH (SEQ ID NO:7)
7. A pharmaceutical composition comprising a cyclic peptide or pharmaceutically acceptable salt thereof of claim 1 and a pharmaceutically acceptable carrier.
8. A method for treating erectile sexual dysfunction, which is responsive to changes in melanocortin receptor function in a human or non-human mammal, comprising the step of administering the pharmaceutical composition of claim 7 .
9. The method of claim 8 , wherein the step of administering comprises oral, parenteral, urethral, vaginal, rectal, nasal, buccal, or sublingual administration.
10. The method of claim 8 , wherein the step of administering comprises subcutaneous administration.
11. The method of claim 8 , further comprising the step of administration of a second erectile sexual dysfunction pharmaceutical agent.
12. A pharmaceutical composition comprising a cyclic peptide or a pharmaceutically acceptable salt thereof of claim 1 and a second sexual dysfunction pharmaceutical agent.